Hidradenitis Suppurativa Pipeline Review, H1 2019 Report – ResearchAndMarkets.com

DUBLIN–()–The “Hidradenitis Suppurativa – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Hidradenitis Suppurativa – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hidradenitis Suppurativa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 2, 9, 1, 5 and 3 respectively.

Hidradenitis Suppurativa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology)

Companies Mentioned

  • AbbVie Inc
  • Aclaris Therapeutics Inc
  • Alvotech Iceland
  • Celgene Corp
  • ChemoCentryx Inc
  • Fresenius SE & Co KGaA
  • Immunwork Inc
  • Incyte Corp
  • InflaRx NV
  • Innovation Pharmaceuticals Inc
  • InSight Biopharmaceuticals Ltd
  • Johnson & Johnson
  • Novartis AG
  • UCB SA
  • XBiotech Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/19cqay

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *